How I treat older patients with AML

Blood

Volumn 96, Issue 5, 2000, Pages 1670-1673

  Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; AGING; CLINICAL PROTOCOL; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; SURVIVAL TIME; TREATMENT PLANNING;

EID: 0034283695     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.5.1670     Document Type: Review

References (36)

1. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission
2. Prognostic factors in cancer clinical trials
3. Graphical methods for evaluating covariate effects in the Cox model
4. Acute myeloid leukemia in the elderly: Assessment of multi-drug resistance (MDR) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest oncology group study
5. A randomized placebo-contolled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
6. Granulo-cyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
7. Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients
8. Implications of potential cure in acute myelogenous leukemia: Development of subsequent cancer and return to work
9. Randomized phase study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte-colony stimulating factor in poor prognosis newly-diagnosed non-APLAML and MDS
10. Validation of a model to predict survival in elderly patients with acute myeloid leukaemia
11. Prognostic factors in elderly patients with acute myeloid leukaemia
12. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group
13. NCCN Acute Leukemia Practice Guidelines: The National Comprehensive Cancer Network
14. Treatment of newly-diagnosed acute myelogenous leukemia in patients age 80 years and above
15. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia
16. Smotdering acute granulocytic leukemia
17. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study
18. Intensive postremission chemotherapy in adults with acute myeloid leukemia
19. Varying intensity of post-remission therapy in acute myeloid leukemia
20. Frequency of prolonged remission duration after high-dose cytosine arabinoside intesification in AML varies by cytogenetic subtype
21. Management of acute myeloid leukemia in elderly patients
22. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly
23. Attenuated high-dose cytosine arabinoside in the treatment of the elderly patient with acute nonlymphocytic leukemia
24. Effect of diagnosis (RAEB, RAEB-t, or AML) on outcome of AML-type chemotherapy
25. Topotecan for myelodysplastic sydromes
26. Combination of topotecan with cyarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
27. A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study
28. Hematopoietic growth factors as, adjuncts to the treatment of acute myeloid leukemia
29. Therapy of acute myelogenous leukemia in hematology
30. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes
31. Efficacy and safety of CMA-676 in patients with AML in first relapse
32. DNA methylation
33. Benefit of cycolporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group study
34. Intravenous busulfan (Busulfex)/cytoxan (CY) preparative regimen for allogeneic (ALLO) and autologous (AUTO) haematopoietic stem cell transplantation (BMT) is well tolerated by patients over 50 years of age
35. Engraftment of allogeneic hematopoietic progentor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
36. A Bayesian strategy for screening cancer treatments prior to phase II evaluation